Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886586 | 0.86 | LMNA (0.43) | MEN1KMT2ALMNACYP1A2CYP2D6 | |
| SCHEMBL4968063 | 0.85 | KMT2A (0.31) | MEN1KMT2ALMNACYP1A2CYP2D6 | |
| SCHEMBL1887608 | 0.79 | — | — | |
| SCHEMBL17675721 | 0.74 | RAB9A (0.37) | MEN1KMT2ALMNA | |
| SCHEMBL1897964 | 0.73 | ALDH1A1 (0.38) | MEN1KMT2ALMNA | |
| SCHEMBL1887766 | 0.73 | — | — | |
| SCHEMBL16863840 | 0.72 | — | — | |
| SCHEMBL17676152 | 0.72 | — | — | |
| SCHEMBL1177997 | 0.70 | — | — | |
| SCHEMBL12922588 | 0.69 | TAS1R3 (0.47) | TAS1R3TAS1R1LMNAUSP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1460994-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003049666-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220074-A1 | Compounds for a controlled release of active molecules | ACLY, PTGES, NOTUM | MEN1 4581/4885KMT2A 4426/4885TAS1R3 1722/4885 |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | ACLY, PTGES, PPOX | MEN1 4691/4885KMT2A 4649/4885TAS1R3 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.